Syndax Pharmaceuticals, Inc.
SNDXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSyndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Valued at $1.19B, SNDX is a small-cap name in its sector. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Market Cap
$1.19B
Beta
0.42
P/E (TTM)
—
P/E (Fwd)
-15.97
EPS (TTM)
$-2.52
EPS (Fwd)
$-0.84
ROE
-255.9%
ROA
-18.7%
Cash
$554.3M
Total Debt
$589.4M
Free CF
-$150.1M
52W Change
-1.0%
Annual Financials
Cash vs Debt
Where SNDX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SNDX finished 35.61% below its 150-day moving average ($20.33) and 36.36% below its 200-day moving average ($20.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNDX overbought or oversold?
At the October 20, 2026 close, SNDX's RSI(14) was 15.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $554.3M in cash, though total debt stands at $589.4M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$150.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -255.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.42 suggests SNDX is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Syndax Pharmaceuticals, Inc. and its sector.